Priya Kaur
Nihal E. Mohamed
Maddison Archer
Mariana G. Figueiro
Natasha Kyprianou- 1Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- 2Light and Health Research Center, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, United States
- 3Tisch Cancer Institute, Mount Sinai Health, New York, NY, United States
- 4Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
The circadian system is an innate clock mechanism that governs biological processes on a near 24-hour cycle. Circadian rhythm disruption (i.e., misalignment of circadian rhythms), which results from the lack of synchrony between the master circadian clock located in the suprachiasmatic nuclei (SCN) and the environment (i.e., exposure to day light) or the master clock and the peripheral clocks, has been associated with increased risk of and unfavorable cancer outcomes. Growing evidence supports the link between circadian disruption and increased prevalence and mortality of genitourinary cancers (GU) including prostate, bladder, and renal cancer. The circadian system also plays an essential role on the timely implementation of chronopharmacological treatments, such as melatonin and chronotherapy, to reduce tumor progression, improve therapeutic response and reduce negative therapy side effects. The potential benefits of the manipulating circadian rhythms in the clinical setting of GU cancer detection and treatment remain to be exploited. In this review, we discuss the current evidence on the influence of circadian rhythms on (disease) cancer development and hope to elucidate the unmet clinical need of defining the extensive involvement of the circadian system in predicting risk for GU cancer development and alleviating the burden of implementing anti-cancer therapies.
Introduction
In 2017, three investigators were jointly awarded the Nobel Prize in Physiology or Medicine for their work on molecular mechanisms controlling the circadian system. The circadian system is an innate clock mechanism that governs biological processes on a near 24-hour cycle (1, 2). The evolutionary-conserved process regulates the sleep-wake cycle as well as molecular and cellular operations. The master clock is located in the suprachiasmatic nuclei (SCN) of the hypothalamus (3). The clock responds to environmental cues, such as light-dark patterns, to allow an individual to maintain synchrony with the external environment (4). In other words, through light-dark signals from the environment, the SCN is synchronized to the local position on Earth (3). In addition, clock genes in the SCN use neural signals to synchronize peripheral clocks located in the body to the external solar day (3). The circadian clock intrinsically drives transcriptional and translational feedback loops (TTFL) that regulate bodily activities (2, 5). The near 24-h cycles of gene expression are promoted by two activator clock proteins, Brain and Muscle ARNT-Like 1 (BMAL1) and Circadian Locomotor Output Cycles Kaput (CLOCK), and two repressor proteins, Period (PER) and Cryptochrome (CRY) (5). Disruption and mutation of the four integral clock proteins can misalign circadian rhythms (CRs, endogenous rhythms that are generated and regulated by then master circadian clock and repeat themselves roughly every 24 hour) such as core body temperature, hormone secretion, and sleep-wake activity (6).
Circadian rhythms disruption (CRDs; which result in misalignment of circadian rhythms, such as hormone production and the sleep-wake cycle have been shown to correlate with increased prevalence and mortality of GU cancers (7). Non-pharmacological interventions including chronotherapy and melatonin have been implicated in the treatment of CRDs. The four integral clock proteins, PER, CRY, BMAL1, and CLOCK, all have complex molecular roles that can improve our understanding of cancer risk and biologically/clinically relevant outcomes (1, 6). Yet, non-pharmacological treatments of chronotherapy and melatonin (e.g., light therapy, behavioral interventions) have diminished the toxicity of chemotherapeutic and immunotherapeutic drugs, while increasing their overall efficacy against aggressive disease (7). In this review we discuss the current evidence recognizing the significant role CRs play in GU cancer risk, development, and treatment outcomes.
Effect of Environmental Cues on CRs
The daily light-dark pattern reaching the retina is the primary input to synchronize the biological clock to the 24-h solar day (6). If humans are not exposed to a sufficient amount of light from the right spectrum for an adequate amount of time, and with the right timing, the biological clock becomes desynchronized with the solar day, resulting in CRDs (8). CRDs are primarily caused by alterations in the circadian clock (i.e., the timekeeping system) or by a misalignment between the endogenous CR (e.g., sleep-wake cycle and hormone production) and the external factors that affect the timing, quality, or duration of sleep (e.g., sleep hygiene, environment, behavior, and social factors) (6, 8). CRDs can profoundly impact physical and daily functioning and have been linked to increased risk of insomnia, heart attacks, immune system imbalance, inflammation, diabetes, and obesity in healthy and chronic disease populations (9–11).
Recent studies confirmed associations between CRDs, increased cancer risk, and worse cancer outcomes (3, 12). Additionally, several environmental and behavioral conditions that may increase CRDs could also be independently associated with increased cancer risks (e.g., jet lag, shift work, and exposure to light at night) (12). Interestingly, a few studies showed that blind individuals with no light perception are less at risk of developing cancer (13, 14). Understanding the molecular mechanisms of the master clock in relation to its role in cell proliferation, DNA damage response, and apoptosis may provide insight into combating cancer incidence and prevalence (15).
CRDs and Increased Risk of Genitourinary Cancer
Evidence suggests that CRDs have a role in an increased risk of cancer progression, leading to unresponsive disease, especially in endocrine-based cancers (16). In the majority of patients treated for genitourinary cancer (GU), including prostate, kidney, and bladder cancer, there is an emergence of tumor recurrence due to therapeutic resistance (17). Prostate cancer (PCa) patients are especially at risk of developing castration-resistant prostate cancer (CRPC) after initially promising therapy with androgen deprivation (ADT) (18). The androgen receptor (AR) remains a prominent driver of therapeutic resistance in PCa (19). AR variants, amplification, and mutations all serve as mechanisms of CRPC progression (19). Despite the implementation of ADT, cells can develop sensitivity to low levels of androgens and lead to treatment-resistance and recurrent fatal disease (19).
In patients with renal cell carcinoma (RCC), there is a progression to chemotherapy-resistant disease that fails to respond to tyrosine kinase inhibitors, although there is burgeoning hope with new small molecule inhibitors (20). The mechanisms of resistance to therapy in RCC are still not fully defined. However, it is hypothesized that angiogenic escape is a possible mechanism that can occur from chronic vascular endothelial growth factor (VEGF) suppression (21). Angiogenic escape involves restoring blood follow in the tumor-associated vasculature, increasing the chances of therapeutic resistance (21).
Metastatic urothelial cancer of the bladder has also been shown to be resistant to immunotherapy and chemotherapy (22). Cisplatin is a key component of chemotherapies treating bladder cancer and is the target of therapeutic resistance (23). There are many ways resistance can arise in bladder cancer, including reduced intracellular accumulation of cisplatin and increased sequestration (23). These factors all enable the cancer cells to elude the therapeutic potential of cisplatin.
Chrono-Pharmacological Treatments of CRDs
Chronotherapy and melatonin are the two most promising non-pharmacological options to improve current anti-cancer drugs. Chronotherapy refers to the optimal dosing time of drugs where high efficacy and low toxicity are achieved (24). Time-dependent dosing relies on the oscillations of genes involved in drug absorption, distribution, metabolism, and excretion (24). Melatonin is a pineal gland hormone and is concurrently released during the hours of sleep (25, 26). However, it also possesses anti-tumorigenic abilities through an unknown mechanism of action (25, 26). Nocturnal melatonin secretion can persists in constant darkness, but exposure to light during the nighttime can suppress the release of the hormone into the bloodstream (25). The endogenous activity of the central clock results in melatonin production, so suppression of melatonin can lead to stimulation of cancer development (27). The possibility of chronotherapy and melatonin supplementation can be applied as a new platform to enhance the efficacy of chemotherapy drugs through precise time-dependent administration (28). A review by Bermu´ dez-Guzma´ and colleagues showed that melatonin, used as adjunct treatment concurrent with chemotherapy or radiotherapy, significantly improved tumor remission and 1-year survival (28). Co-administering melatonin and cancer treatments could also result in the patient having fewer adverse effects and improved outcomes (29).
Critical Effectors of the Circadian Clock
The regulation of the CRs occurs at the transcriptional level. There are four key circadian clock proteins: BMAL1, PER (1–3), CLOCK, and CRY (1-2) (Figure 1) (30). Brain and Muscle Arnt-like protein, also known as BMAL1, is an integral transcription factor (31). It is a known activator of the master clock and is present in the transcriptional feedback loop (32). REV-ERBα (NR1D1) and RORα are two major nuclear receptors involved in the regulatory loop for BMAL1 (Figure 1) (33, 34). The heterodimer of BMAL1 and CLOCK binds to the E-box motif and activates the transcription of REV-ERBα, RORα, two repressor proteins, PER and CRY, as well as other clock-controlled genes (CCGs) (Figure 1) (32). CRY is known to be the primary driver of the circadian oscillator through repressing the CLOCK : BMAL1 heterodimer (Figure 1) (35). PER2 is the sole protein that interacts with CLOCK, whereas both PER and CRY proteins interact with BMAL1 (36). Future research on the binding and repression of the CLOCK : BMAL1 transcriptional activity will clarify the other regulatory roles of the proteins in the CRs (36).
Figure 1 Genetic Outcomes of the Circadian Clock Proteins and Clinical Management Techniques. Circadian clock transcription-translation feedback loop (TTFL) is controlled by two activator proteins Brain and Muscle ARNT-Like 1 (BMAL1) and Circadian Locomotor Output Cycles Kaput (CLOCK), and two repressor proteins, Period (PER) and Cryptochrome (CRY). BMAL1 and CLOCK heterodimerize and bind to the E-box motif to activate the transcription of CRY (1-2), PER (1-3), clock-controlled genes (CCGs), RORα, REV-ERBα. CRY and PER establish the primary negative feedback loop by inhibiting the BMAL1 and CLOCK heterodimer. In the secondary feedback loop, RORα activates, and REV-ERBα inhibits the transcription of BMAL1. Circadian clock proteins mediate several cancer pathways such as cell cycle regulation, DNA damage repair, apoptosis, and hormonal changes. Melatonin binds to the MT1 and MT2 receptors and targets inflammation and survival pathways by preventing the translocation of NF-κB to the nucleus. Melatonin interferes with EMT and metastasis by downregulating β-catenin through activation of GSK-3β and inhibiting the expression of matrix metalloproteinases-9 and -13. The inhibition of endothelin-1 (ET-1) by melatonin leads to reduced activity of angiogenic factors HIF-1α and VEGFA.
Disruption of gene expression may lead to diseases since the clock proteins are involved in several transcriptional pathways. For instance, it was found that if the PER2 gene is downregulated, there is an increased risk for breast cancer (37). In contrast, if the PER2 gene is overexpressed, it may confer tumor-suppressive properties (38). In colorectal cancer, increased levels of BMAL1 have been related to decreased survival, and similarly, reduced levels of PER2 and PER3 have led to more inadequate tumor differentiation (39). Other studies have found that the clock gene expressions were reduced to 60% in melanoma and naevus tumors, highlighting their role in transcription regulation and tumorigenesis (40). With increasing evidence, research suggests that the clock proteins are also involved in genotoxic stress and aging, which are two factors that can also lead to carcinogenesis (41). Thus, disturbances of the circadian clock gene expression leading to interesting downstream effects can play a role in the carcinogenesis of various cancers.
Other factors, such as exposure to light at the wrong circadian time (e.g., exposure to ambient electric light during night shifts) or not enough light exposure at the right circadian time (e.g., not enough exposure to daylight), can alter the timing of the biological clock in humans (42). In particular, melatonin, a pineal gland hormone, can be affected by the amount and distribution of light signals picked up by the retina (43). With increased exposure to light at night, blood melatonin levels may be suppressed, leading to CRDs (43). Melatonin influences CRY1 expression, and melatonin suppression resulting from increased exposure to light at night, can compromise CRY1’s function in regulating CRs (44). Thus, electric light at night in the environment can disrupt pineal function and thus be linked to a higher incidence of hormone-related cancers such as PCa and breast cancer (43). The indirect light-induced stimulation of tumor development may be associated with the inhibitory clock proteins PER1 and PER2 (44). Specifically, disrupting PER2, CRY2, or BMAL1 in various tissues can increase the likelihood of cancer development (44). A light-induced signaling pathway is also involved in regulating the cell division cycle (44, 45). AP-1 is a transcription factor involved in maintaining biological processes, such as cell proliferation and apoptosis (45), and was found to have light-dependent activation in the SCN, adding to evidence that light plays a vital role in cancer development and circadian rhythm regulation (45).
CRDs and GU Cancers
Prostate Cancer
Prostate cancer (PCa) is the second most frequent cancer diagnosis made in men with 1,276,106 new cases of reported worldwide in 2018 (46). In the United States, an estimated 248,530 new cases and 34,130 deaths are estimated in 2021 (47). Although differences in PCa incidence rates worldwide reflect differences in the use of diagnostic testing and PCa screening guidelines, both incidence and mortality rates are strongly related to age with the highest incidence being seen in elderly men (> 65 years of age) (46). In the United States, PCa screening is highly recommended at age 40 for men with familial history and men of African ancestry (48).
For early stage PCa patients survival is 99% for the first five years after localized treatment (49). However, eventually, many PCa patients develop therapeutic resistance to ADT, otherwise known as castration-resistant prostate cancer (CRPC) (50). This leads to an incurable disease in which 19.5% of patients died from metastatic-CRPC in 2020 (51). There has been a recent shift to using taxane-based chemotherapy to treat CRPC patients (52). Taxanes are an excellent option for resistant PCa as they stimulate apoptosis by disrupting the G2/M-phase of the cell cycle (53). Despite the benefits of taxanes, 1st and 2nd line taxane chemotherapy (Docetaxel and Cabazitaxel, respectively) in patients with advanced metastatic disease, ultimately, emergence of therapeutically resistant tumors leads to lethality.
Significantly enough, disruption of CRDs have been implicated in PCa risk and progression (54). Compelling evidence suggests a significant correlation between light exposure at night and increased PCa incidence (54). Additional studies from independent investigators have exploited melatonin suppression and shift work and their positive correlations with PCa risk (55, 56). Increased risk of PCa among night male shift workers is attributed to changes in amplitude of melatonin and associated changes in sex hormone secretion that contribute to Epithelial-to-mesenchymal transition (EMT) typically involved in PCa development (55, 56). Two pathways may result in reduced amplitude of melatonin among male night shift workers; a) the acute melatonin suppression through exposure to electric light after dusk (57); and b) the decreased melatonin levels through CRDs (58), that consequentially results in desynchronization of the peripheral clocks, promoting cell growth and tumor development (58). Melatonin may suppress PCa growth by down regulating transcription, secretion, or activity of growth factors; it may stimulate the immune system through increased production of interleukin-2 and interleukin-4 by T-helper cells; lastly, it may protect DNA against oxidative damage by scavenging free radicals (58). It is thus apparent that disruption of the CRs can lead to increased PCa risk (Table 1). Moreover, growing evidence supports an intricate relationship between PCa, and the effector proteins functionally associated with the circadian clock. These proteins regulate cancer mechanisms such as apoptosis or proliferative cancers (58, 59). A study found that PER2 and CLOCK protein levels were downregulated, and in contrast, BMAL1 was upregulated in PCa tissue (60). Another circadian repressor protein, CRY1, is a known regulator of cell proliferation and DNA repair (61). CRY1 was upregulated in PCa and thus indicated a poor outcome for metastatic-CRPC (61). Like many clock proteins, CRY1 has transcriptional control aside from its role in regulating the circadian clock (61). Clock proteins are crucial for the proper functioning of the cell, especially in the case of cell growth/death, homeostasis, metabolism, and hormone release (60). When protein expression is disturbed, the CRs are also disrupted, which can amount to several disease states such as PCa (61). The mechanistic underpinnings of these proteins are still being studied and could provide profound insight into designing molecular therapies to treat cancers (62, 63).
Table 1 Genetic Involvement of the circadian system in GU cancers and clinical management options.
The tumor microenvironment is a critical biological dynamic entity that merits exploitation in functional exchange with the external environment (light, temperature, specifically impacted by the circadian clock). EMT in solid tumors (including PCa) has been defined to play a significant role in cancer and a major contributor to metastasis (64). EMT is characterized by the loss of cell-cell adhesion, increased cell motility, and reduced E-cadherin expression, a structural adhesion molecule (65). E-cadherin, a calcium-dependent protein involved in cell-cell adhesion, is crucial for preventing PCa cells from migrating to bones to facilitate metastatic disease (66). Some several molecular mechanisms and pathways influence EMT, such as epidermal growth factor (EGF) and mitogen-activated protein kinase (MAPK) (67). Changes in signaling pathways ultimately alter the expression of transcription factors such as Snail and Zeb-1 (67). As a result of activation of these transcriptional repressors, E-cadherin expression levels are repressed, ultimately leading to enhanced mesenchymal and migratory markers in mesenchymal cells (68). Thus, EMT is functionally linked to promoting PCa metastatic progression, leading to stemness, therapeutic resistance, and ultimately lethal disease (68). Work from our group demonstrated that interconversion of EMT to mesenchymal-to-epithelial transition (MET) is observed in advanced PCa pre-clinical models in response to treatment with the second line taxane chemotherapy, cabazitaxel (52). This dynamically transient EMT-MET cycling allows cabazitaxel to prime the cells to retain a non-migratory phenotype, reducing the chances of metastasis (52). There is an ongoing effort to identify a temporal therapeutic window that can enable cells to overcome resistance by anti-androgen action (52).
Similar to phenotypic EMT navigating PCa, chronic CRs has been demonstrated to lead to the metastatic spread of breast cancer (65). CRs have a role in hormone expression and promote an immunosuppressive phenotype in endocrine-related cancers (69). Circadian-regulated transcription factors, such as PER2 and BMAL1, can regulate EMT through influencing EMT signaling effectors responsible for stemness and cell migration (69). Downregulated PER2 was associated with a higher likelihood of EMT in breast tissue, while downregulated BMAL1 decreased the invasion of mesenchymal cells in colorectal cancer (69). Melatonin was also found to regulate EMT and molecular pathways underlying the phenotypic conversion and cell invasiveness (65). MLT can activate GSK3β, an enzyme involved in cell proliferation, which reduces β-catenin levels, and subsequently leads to restoration of E-cadherin in human breast cancer cells (Figure 1) (65).
Kidney Cancer
Kidney cancer accounted for nearly 431,300 cases worldwide in 2020 and has been increasing in recent years (70, 71). The median age of diagnosis is 65 years (72) (Table 1). Many tumors comprise kidney cancer, with 90% being RCC cases (73). Within the various molecular subtypes of RCC, clear cell RCC leads to the most deaths (73). The mortality rate of 30-40% for RCC is significantly greater than prostate and bladder cancers (74). Kidney cancer tends to be resistant to chemotherapy and radiation therapy, making immunotherapy the best option (75). With increased attention on potential mechanisms of progression such as angiogenesis and altered hypoxia signals, CRs research could explore ways to reduce the disease burden (76). Circadian pathways help maintain physiological fluctuations, such as water transport and essential renal function (77). Almost 43% of all protein-coding genes throughout the body showed CRs in transcription, many of them being in the kidney (77, 78). These gene expressions peak right before dawn and dusk (78). In a study linking the dysregulation of the circadian clock and RCC, clock genes were transcriptionally different in diseased versus healthy tissue (79). For example, CLOCK, CRY1, and CRY2 levels were downregulated in kidney cancer tissue (80). Patients that retained high levels of CLOCK had a better prognosis than those without (80). Like PCa, the clock proteins significantly predict the risk and progression of kidney cancer through intricate molecular mechanisms.
The clock proteins are crucial for regulating CRs and immune system function (81). The immune checkpoint pathway is suppressed when the clock protein BMAL1 is downregulated, causing sepsis (81). Sepsis and cancer share many immunological properties, so immunomodulatory agents could successfully treat both diseases (81). Increased expression of PD-1 and its ligand, PD-L1, help stimulate tumor-directed cytotoxic T cell function in both sepsis and cancer (81). The loss of the clock gene, BMAL1, showed increased PD-L1 expression in macrophages, which is associated with poorer sepsis survival (81).
Bladder Cancer
Bladder cancer is ranked in the top ten most common cancers worldwide (82). Around 2.1% of cancer deaths are caused by urinary bladder cancer (UBC) each year, resulting in a high mortality rate (47). In Europe, the five-year survival rate for UBC was 68% (83). Unlike PCa, UBC has poorer outcomes within five years of being diagnosed. However, it has a higher survival rate than kidney cancer in Europe, which is 60% (83). UBC follows a similar prevalence trend of other GU cancer. It is less common in sub-Saharan Africa, India, and Mongolia and more common in Western Europe and Australia (84). The geographic distribution may be partly explained by exposure to tobacco, environmental pollutants, and occupational carcinogens, which are invariably linked to UBC incidence (85).
UBC can develop into either muscle-invasive bladder cancer (MIBC) or non-muscle-invasive bladder cancer (NMIBC) (86). For NMIBC, the course-of-treatment usually involves maintenance immunotherapy, whereas MIBC often requires chemotherapy (86). Combination chemotherapy provides good outcomes initially in impairing tumor growth, but it ultimately fails as cancer cells develop therapeutic resistance (87). Cisplatin is a first-line chemotherapy treatment that directly interacts with the circadian clock proteins and enhances the body’s natural response to cancerous cells (88). It upregulates CLOCK and BMAL1, resulting in increased proliferation and increased apoptosis, respectively (88). In bladder cancer tissue from human specimens, BMAL1 was downregulated, and CLOCK was upregulated, so cisplatin acts differently on both proteins through unclear mechanisms (89). Cisplatin has multiple opposing effects on tumor growth, resulting in stimulating pro-cancer effects (88). Thus our current understanding begs the question of interrogating the impact of disruption of circadian clock proteins on the molecular mechanisms underlying cell proliferation and apoptosis. In the context of contributing to therapeutic resistance, another clock protein, CRY1, was found to inhibit paclitaxel-induced senescence in bladder cancer cells (90). Typically, in urothelial tumors, CRY1 has been detected to be downregulated (89). While senescence causes cells to halt dividing, it also provides a way for cancer cells to become resistant to treatment (91). When the second-line therapy of paclitaxel is used, it prevents cell arrest and promotes the degradation of p53 (90). Healthy adults continually degrade p53, which is a tumor suppressor to stimulate p53 turnover (92). CRY1 is crucial in preventing the senescence induced by paclitaxel and delaying drug resistance (90).
The Circadian Clock as the New Frontier to Overcome Therapeutic Resistance
Melatonin Treatment
Melatonin (MLT) is a pineal gland hormone that can phase shift the SCN and provide timing information to the body (93). The pineal gland is crucial in regulating tumor growth and could become a target for therapeutics development (94). Melatonin levels naturally increase during dusk and taper off at dawn (95). Interestingly, subjects in perpetual darkness, such as visually impaired individuals, still display a 24.2-h cycle of melatonin and can have typical endogenous CRs (96).
The molecular mechanisms via which melatonin influences tumor cell proliferation and cancer metabolism are not clearly defined. Growing evidence suggests that melatonin may decrease the activity of endothelin-1 (ET-1), leading to downstream effects of downregulating hypoxia-inducible factor 1 alpha (HIF-1α) and VEGF, which both contribute to promoting angiogenesis (Figure 1) (97, 98). Preventing angiogenesis remains a critical goal to impair metastasis of kidney cancer (21). Significantly, it can also regulate breast cancer growth through two membrane melatonin receptors, MT1 and MT2, which are expressed in breast tissue, and impact survival signaling pathways (97). An overall decrease in melatonin levels has been associated with a higher risk of cancer, neurological disorders, and sleeping disorders (99). Thus, melatonin proves to be an effective and attractive therapy to improve the efficacy to toxicity ratio of anti-cancer drugs (100).
One of the most well-known hypotheses is that MLT is an epigenetic regulator that can prevent tumor growth by inhibiting telomerase activity and regulating linoleic acid uptake and metabolism, both crucial to proliferation (101). Circadian-dependent administration of MLT may confer tumor-suppressive properties (102). Melatonin has also been a potent, safe, and low-cost therapeutic in cancer research (103). A randomized controlled trial of solid tumors found that MLT reduces death by nearly a year (103). MLT also stimulates a robust chemotherapy response in palliative cancer care compared to receiving only supportive care (104). The patient’s quality of life is improved by reducing the side effects such as asthenia and thrombocytopenia (104). Thus, melatonin may enhance the therapeutic efficacy of patients with resistant GU cancers.
Despite the uncertainty that surrounds melatonin’s impact on cancer as a clinical disease, its protective benefits in human PCa are becoming increasingly evident. Men with high levels of urinary melatonin were less likely to develop advanced PCa (105). Advanced PCa is characterized by metastasis which involves tumor migration and invasion and ultimately lethal disease (106). Approximately 80% of patients with advanced PCa develop bone metastasis, a process that is linked with the expression of matrix metalloproteases (MMP) (107). Matrix metalloproteases are proteolytic enzymes responsible for breaking down connective tissue and allowing tumors to invade other tissues (108). MLT downregulates MMP-13 expression, which may suppress the metastasis of PCa (Figure 1) (109). MMP-13 is another excellent target for future therapeutic studies of PCa. It is of major significance to understand the molecular mechanisms driving the anti-tumor and anti-invasion properties of this agent.
MLT inhibits bladder and kidney cancer growth and metastasis (109). MLT prevents the nuclear translocation of NF-κB and decreases the expression of pro-inflammatory intermediates (Figure 1) (110). Recent studies have shown that MLT treatment resulted in increased apoptosis through NF-κB regulation in human gastric (111) and bladder cancer cells (110, 112). Moreover, MLT suppresses the Akt/MAPKs pathway and downregulates MMP-9, crucial for RCC progression (113). Through binding to the active site of MMP-9, MLT can arrest associated inflammatory signals that contribute to tumor growth (Figure 1) (114). Given the rapidly growing evidence at the mechanistic level, one could propose that MLT confers considerable transcriptional and post-translational control that are still not well understood.
Chronotherapy
Chronotherapy involves orchestrating the timing of treatment administration to match the body’s endogenous CRs (115). This method has shown unequivocal success in tumor outcome and improved management of the disease (116). In addition, circadian dosing is crucial in limiting the toxicity of anti-cancer drugs and maximizing their efficacy (115). A characteristic example of an optimized (time-dependent response) is the first-line taxane chemotherapy, docetaxel, which is shown to have the best clinical outcome if administered in PCa patients between 6 and 9 am (115).
One must also consider that many cancer patients in late stages report having increased CRD with irregular sleep schedules (117). In breast cancer specifically almost 72% of advanced cancer patients display moderate-to-severe sleep disturbances (118). Chronotherapy could reduce the side effects of chemotherapy while also promoting a strong therapeutic response. In a retrospective study, patients undergoing high-dose radiotherapy for PCa in the evening had more GI complications than those in the morning (119). The toxicity of the drug is also decreased when administering the treatment in alignment with circadian oscillations. Lower toxicity levels could significantly relieve patients who have PCa, especially since GU cancer patients are older on average (119). There should also be a shift to similarly evaluating circadian-based dosing in therapy-resistant cancer patients. A circadian-modified infusion schedule can also allow clinicians to administer higher drug doses to induce a powerful response without the lethal toxicity. For example, patients with RCC could receive higher doses of floxuridine on a circadian-modified infusion schedule than on a continuous infusion schedule (120). This provides unique opportunities for a rigorous and impactful treatment of GU cancers while in their non-resistant phases for a better outcome. Chronotherapeutic schedules can also increase long-term survival and overall quality of life while on chemotherapies, such as oxaliplatin for metastatic colorectal cancer (121). In patients with metastatic UBC, treatment with doxorubicin-cisplatin resulted in a 57% objective response rate when coupled with chronotherapy (122). Other therapeutic options such as interferon-alpha and IL-2 (Interleukin-2) are promising agents to slow metastatic RCC, but they come at the risk of significant toxicity (122). By optimizing drug administration when toxicity would be minimized, clinicians can better use readily available compounds to treat GU cancers (122). Chronotherapy is not limited to only chemotherapy and immunotherapy in enhancing their treatment response outcomes. It can also be applied to radiation techniques, such as proton beam therapy (PBT), which directs smaller radiation doses at localized PCa (123). PBT was observed to have less severe lower urinary tract symptoms when given in the morning than in the afternoon (123).
Personalized medicine approaches can pave treatment strategies towards increasing patient survival and improving the quality of life for cancer patients. One may also consider that specializing current treatment methods according to a person’s chronotype, defined as a person’s preference for timing of sleep and activity, may lead to improved clinical outcomes. While chronotherapy has provided encouraging results in rendering cancer therapies more tolerable, more clinical studies are warranted. A significant issue is that much of the current research on chronotherapy in anti-cancer drugs do not have a strict time interval. Without a specific period, it is difficult for clinicians to administer treatment at the optimal time for maximum efficacy. Thus, there is an unmet need to functionally define the role of the CRs in cancer research.
Environmental and Behavioral Interactions
Prior work in chronic disease patient populations suggests significant effects of environmental and behavioral interventions on reducing CRDs, including light therapies, physical activities, and diet modification which could, in turn, improve cancer patient outcomes (124, 125). Light is the strongest synchronizer of CRs, and exposure to ambient light at the right time could reduce CRDs and, thus, improve cancer patient physical and functional outcomes (126–130). Endocrine disruption due to exposure light during the circadian night has been implicated as carcinogenic, both in animal studies and in epidemiological studies in humans (131).
Evidence also suggests that physical activity could affect CRs (132–134). It has been shown that 1–3 hours of intense exercise can induce significant circadian phase shifts depending on the duration, intensity, and frequency of physical activities (132–134). Studies showed that early morning physical activities are associated with phase delays in the circadian clock (134, 135). However, early morning exercise offered protective effects for breast and PCa patients with an evening chronotype (136). Other studies showed that physical activities later at night induced phase delays in melatonin secretion (137). Individuals placed on prolonged periods of bed rest without exercise also show a circadian phase delay (125). Circadian misalignment is also observed when individuals participate in restrictive movement of one limb but not the other (125). This selective exercise leads to changes in the regulation of the clock genes, which are implicated in cancer pathways (Figure 1) (125). Additional assessment of the optimal time to exercise that can mitigate increased cancer risk and CRDs (124). One must note here that, while some studies show that exercise can alter circadian phase, its impact on the circadian clock is significantly less than the impact of light-dark patterns reaching the retina.
Lifestyle patterns in feeding/meal consumption (e.g., late-night meals) and diet programs (e.g., high fat diet) have been found to also influence circadian patterns in humans, although behavioral and sociocultural factors often control this (124). These circadian eating patterns are mirrored by both the gastrointestinal system, leading to rhythms in digestive secretions, gut motility, absorption of digested food, and blood nutrient concentrations (124). Feedback loops exist between the hormones controlling the circadian clock and those directing appetite and satiety, such as leptin, orexin, and ghrelin (124). Considering the roles of clock-related hormones, a food-entrainable circadian clock in humans may be present (124, 138, 139). Food-based entrainment enhances the synchronization of the peripheral and master clock, which can positively impact cancer regulation (124). Thus, in addition to understanding the impact of light exposure patterns, a further investigation into the interactive impact of exercise, diet, and nutrition on the risk, development, and clinical outcomes of GU cancers is likely to be impactful.
Conclusion
A systematic review and meta-analysis of the previous studies in breast cancer female patients revealed a positive relationship between indicators of CRDs (e.g., nightshift work) and breast cancer risk (58). Changes in hormone secretion, caused by CRDs, was proposed as a contributing factor to the observed increase in breast cancer risk (58). Although breast cancer occurs predominantly in women, the biology and epidemiology of breast cancer share some similar features of GU cancer specially PCa (57, 58). For example, tumor progression in both breast cancer and PCa is strongly affected by sex hormones, which are, to a larger extent, influenced by CRDs and reduced amplitude of nighttime hormone melatonin.
The role of the CRs extends past currently known molecular regulations in transcription and translation. Given the extensive part of the four clock proteins (CRY, PER, BMAL1, and CLOCK), the circadian clock may regulate many cancer mechanisms such as apoptosis and therapeutic resistance (140, 141). Advanced GU cancers have poor outcomes and high mortality rates, making the development of therapeutic targets a time-sensitive task (142). A pioneering research study of circulating tumor cells, which are biomarkers of metastasis, has shown to follow specific circadian rhythmicity in animal models of PCa (143). By targeting PCa treatment to coincide when circulating tumor cells are at their highest concentration in the bloodstream, clinicians may be able to produce robust patient responses to treatment (143). Chronotherapy and MLT supplementation have also both proven to increase the efficacy of various chemotherapies and immunotherapies (121, 144). These are underused and beneficial tools that can diminish disease burden and progression.
Moving forward, the focus is the pursuit of CRs as defense mechanisms the body can engage to optimize therapeutic responses in patients diagnosed and treated for GU cancers. Circadian-based treatments can modulate the pharmacological ability of anti-cancer drugs towards improving therapeutic outcomes and be potentially incorporated into clinical trials for treatment optimization and improved patient survival. One may argue that the simple method of syncing drug administration with the body’s endogenous circadian clock can maximize the efficacy of clinically approved treatment strategies in managing advanced GU cancers. Moreover, the circadian clock provides an informative new platform about the optimal timing and dosing of the drug, compared to traditional pharmacokinetics and pharmacodynamics. Given the impact of the circadian clock on cancer progression and treatment response, the promise of enabling a viable defense against the GU tumors emerges. Driven by advanced technology, ongoing efforts from different centers focus on defining the roles of the clock proteins and their downstream effects in progression and clinical management of GU cancers to advanced disease. Thus whole-genome approaches, genomics, and proteomics would enable the detection of protein expression patterns and temporal networks of the clock proteins. Moreover, clinical studies implementing chronotherapy and melatonin supplementation are currently lacking in large patient cohorts ranked by their circadian profiles. The circadian-rhythms-navigated therapies pave the way for more effective implementation of current treatment modalities, their optimization towards overcoming therapeutic resistance and improving the quality of life in patients with GU malignancies.
Author Contributions
Conceptualization: NM, PK, NK, MF. Resources: NM, MF, NK. Writing: PK, NM, MA, MF, MK. Figure preparation: MA, PK. Review and Editing: MF, NK. All authors contributed to the article and approved the final submitted version.
Funding
This work was supported by the following funding: Grant # R01 CA232574/National Institutes of Health/NCI (NK); Grant #R01OH01668/NIH/NIOSH (MF); Department of Defense W81XWH-17-1-0590 #PC160194 and the National Institute of Nursing Research (1R21 NR0165)18-01A1 (NM).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
The authors recognize the Icahn School of Medicine at Mount Sinai Summer Undergraduate Research Program (for supporting PK). Figure 1 was produced using BioRender.com.
Abbreviations
ADT, androgen deprivation therapy; Akt, protein kinase B; MAPKs –mitogen-activated protein kinase; AR, androgen receptor; BMAL1, Brain and Muscle ARNT-Like; CCGs, clock-controlled genes; CRDs, circadian rhythms disruption; CR, circadian rhythms; CLOCK, Circadian Locomotor Output Cycles Kaput; CRPC, castration-resistant prostate cancer; CRY, cryptochrome; EGF, epidermal growth factor; EMT, epithelial-to-mesenchymal transition; ET-1, endothelial-1; GSK-3β, glycogen synthase kinase-3β; GU, genitourinary; HIF-1α, hypoxia-inducible factor 1 alpha; IL-2, interleukin-2; MAPK, mitogen-activated protein kinase; MET, mesenchymal-to-epithelial transition; MIBC, muscle-invasive bladder cancer; MLT, melatonin; MMP, matrix metalloprotease; NMIBC, non-muscle-invasive bladder cancer; PBT, proton beam therapy; PCa, prostate cancer; PER, period; RCC, renal cell carcinoma; REV-ERBα (NR1D1), nuclear receptor subfamily 1 group D member 1; RORα, retinoid-related orphan receptor alpha; RORE, retinoid-related orphan receptors response elements; SCN, suprachiasmatic nuclei; TTFL, transcriptional and translational feedback loop; UBC, urinary bladder cancer; VEGF, vascular endothelial growth factor.
References
1. Sulli G, Lam MTY, Panda S. Interplay Between Circadian Clock and Cancer: New Frontiers for Cancer Treatment. Trends Cancer (2019) 5(8):475–94. doi: 10.1016/j.trecan.2019.07.002
2. Sahar S, Sassone-Corsi P. Metabolism and Cancer: The Circadian Clock Connection. Nat Rev Cancer (2009) 9(12):886–96. doi: 10.1038/nrc2747
3. Shafi AA, Knudsen KE. Cancer and the Circadian Clock. Cancer Res (2019) 79(15):3806–14. doi: 10.1158/0008-5472.CAN-19-0566
4. Partch CL, Green CB, Takahashi JS. Molecular Architecture of the Mammalian Circadian Clock. Trends Cell Biol (2014) 24(2):90–9. doi: 10.1016/j.tcb.2013.07.002
5. Chiou YY, Yang Y, Rashid N, Ye R, Selby CP, Sancar A. Mammalian Period Represses and De-Represses Transcription by Displacing CLOCK-BMAL1 From Promoters in a Cryptochrome-Dependent Manner. Proc Natl Acad Sci USA (2016) 113(41):E6072–e9. doi: 10.1073/pnas.1612917113
6. Koch BC, Nagtegaal JE, Kerkhof GA, ter Wee PM. Circadian Sleep-Wake Rhythm Disturbances in End-Stage Renal Disease. Nat Rev Nephrol (2009) 5(7):407–16. doi: 10.1038/nrneph.2009.88
7. Altman BJ. Cancer Clocks Out for Lunch: Disruption of Circadian Rhythm and Metabolic Oscillation in Cancer. Front Cell Dev Biol (2016) 4:62. doi: 10.3389/fcell.2016.00062
8. Figueiro MG. Disruption of Circadian Rhythms by Light During Day and Night. Curr Sleep Med Rep (2017) 3(2):76–84. doi: 10.1007/s40675-017-0069-0
9. Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-H Rest/Activity Rhythms Are Associated With Better Quality of Life, Better Response, and Longer Survival in Patients With Metastatic Colorectal Cancer and Good Performance Status. Clin Cancer Res Off J Am Assoc Cancer Res (2000) 6(8):3038–45.
10. Levin RD, Daehler MA, Grutsch JF, Quiton J, Lis CG, Peterson C, et al. Circadian Function in Patients With Advanced Non-Small-Cell Lung Cancer. Br J Cancer (2005) 93(11):1202–8. doi: 10.1038/sj.bjc.6602859
11. Walker WH, Walton JC, DeVries AC, Nelson RJ. Circadian Rhythm Disruption and Mental Health. Trans Psychiatry (2020) 10(1):28. doi: 10.1038/s41398-020-0694-0
12. Erren TC, Pape HG, Reiter RJ, Piekarski C. Chronodisruption and Cancer. Die Naturwissenschaften (2008) 95(5):367–82. doi: 10.1007/s00114-007-0335-y
13. Flynn-Evans EE, Stevens RG, Tabandeh H, Schernhammer ES, Lockley SW. Total Visual Blindness Is Protective Against Breast Cancer. Cancer Causes Control CCC (2009) 20(9):1753–6. doi: 10.1007/s10552-009-9405-0
14. Lockley SW, Arendt J, Skene DJ. Visual Impairment and Circadian Rhythm Disorders. Dialogues Clin Neurosci (2007) 9(3):301–14. doi: 10.31887/DCNS.2007.9.3/slockley
15. Wood PA, Yang X, Hrushesky WJ. Clock Genes and Cancer. Integr Cancer therapies (2009) 8(4):303–8. doi: 10.1177/1534735409355292
16. Russart KLG, Nelson RJ. Light at Night as an Environmental Endocrine Disruptor. Physiol Behav (2018) 190:82–9. doi: 10.1016/j.physbeh.2017.08.029
17. Zarrabi K, Paroya A, Wu S. Emerging Therapeutic Agents for Genitourinary Cancers. J Hematol Oncol (2019) 12(1):89. doi: 10.1186/s13045-019-0780-z
18. Begemann D, Wang Y, Yang W, Kyprianou N. Androgens Modify Therapeutic Response to Cabazitaxel in Models of Advanced Prostate Cancer. Prostate (2020) 80(12):926–37. doi: 10.1002/pros.24015
19. Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of Resistance in Castration-Resistant Prostate Cancer (CRPC). Trans Andrology Urol (2015) 4(3):365–80. doi: 10.3978/j.issn.2223-4683.2015.05.02
20. Siska PJ, Beckermann KE, Rathmell WK, Haake SM. Strategies to Overcome Therapeutic Resistance in Renal Cell Carcinoma. Urologic Oncol (2017) 35(3):102–10. doi: 10.1016/j.urolonc.2016.12.002
21. Rini BI. New Strategies in Kidney Cancer: Therapeutic Advances Through Understanding the Molecular Basis of Response and Resistance. Clin Cancer Res an Off J Am Assoc Cancer Res (2010) 16(5):1348–54. doi: 10.1158/1078-0432.CCR-09-2273
22. Wołącewicz M, Hrynkiewicz R, Grywalska E, Suchojad T, Leksowski T, Roliński J, et al. Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. Cancers (2020) 12(5):1181. doi: 10.3390/cancers12051181
23. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular Mechanisms of Cisplatin Resistance. Oncogene (2012) 31(15):1869–83. doi: 10.1038/onc.2011.384
24. Dong D, Yang D, Lin L, Wang S, Wu B. Circadian Rhythm in Pharmacokinetics and its Relevance to Chronotherapy. Biochem Pharmacol (2020) 178:114045. doi: 10.1016/j.bcp.2020.114045
25. Zhdanova IV, Lynch HJ, Wurtman RJ. Melatonin: A Sleep-Promoting Hormone. Sleep (1997) 20(10):899–907. doi: 10.1093/sleep/20.10.899
26. Menéndez-Menéndez J, Martínez-Campa C. Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers. Int J Endocrinol (2018) 2018:3271948. doi: 10.1155/2018/3271948
27. Blask DE. Melatonin, Sleep Disturbance and Cancer Risk. Sleep Med Rev (2009) 13(4):257–64. doi: 10.1016/j.smrv.2008.07.007
28. Bermúdez-Guzmán L, Blanco-Saborío A, Ramírez-Zamora J, Lovo E. The Time for Chronotherapy in Radiation Oncology. Front Oncol (2021) 11:687672. doi: 10.3389/fonc.2021.687672
29. Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI. Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities. Molecules (2021) 26(9):2506. doi: 10.3390/molecules26092506
30. Ye R, Selby CP, Chiou YY, Ozkan-Dagliyan I, Gaddameedhi S, Sancar A. Dual Modes of CLOCK:BMAL1 Inhibition Mediated by Cryptochrome and Period Proteins in the Mammalian Circadian Clock. Genes Dev (2014) 28(18):1989–98. doi: 10.1101/gad.249417.114
31. Kiyohara YB, Tagao S, Tamanini F, Morita A, Sugisawa Y, Yasuda M, et al. The BMAL1 C Terminus Regulates the Circadian Transcription Feedback Loop. Proc Natl Acad Sci USA (2006) 103(26):10074–9. doi: 10.1073/pnas.0601416103
32. Menet JS, Pescatore S, Rosbash M. CLOCK:BMAL1 is a Pioneer-Like Transcription Factor. Genes Dev (2014) 28(1):8–13. doi: 10.1101/gad.228536.113
33. Solt LA, Kojetin DJ, Burris TP. The REV-ERBs and RORs: Molecular Links Between Circadian Rhythms and Lipid Homeostasis. Future medicinal Chem (2011) 3(5):623–38. doi: 10.4155/fmc.11.9
34. Duez H, Staels B. Rev-Erb-Alpha: An Integrator of Circadian Rhythms and Metabolism. J Appl Physiol (Bethesda Md 1985) (2009) 107(6):1972–80. doi: 10.1152/japplphysiol.00570.2009
35. Ishikawa T, Hirayama J, Kobayashi Y, Todo T. Zebrafish CRY Represses Transcription Mediated by CLOCK-BMAL Heterodimer Without Inhibiting its Binding to DNA. Genes to Cells devoted to Mol Cell Mech (2002) 7(10):1073–86. doi: 10.1046/j.1365-2443.2002.00579.x
36. Langmesser S, Tallone T, Bordon A, Rusconi S, Albrecht U. Interaction of Circadian Clock Proteins PER2 and CRY With BMAL1 and CLOCK. BMC Mol Biol (2008) 9:41. doi: 10.1186/1471-2199-9-41
37. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated Expression of the PER1, PER2 and PER3 Genes in Breast Cancers. Carcinogenesis (2005) 26(7):1241–6. doi: 10.1093/carcin/bgi075
38. Miyazaki K, Wakabayashi M, Hara Y, Ishida N. Tumor Growth Suppression In Vivo by Overexpression of the Circadian Component, PER2. Genes to Cells Devoted to Mol Cell Mech (2010) 15(4):351–8. doi: 10.1111/j.1365-2443.2010.01384.x
39. Karantanos T, Theodoropoulos G, Pektasides D, Gazouli M. Clock Genes: Their Role in Colorectal Cancer. World J Gastroenterol (2014) 20(8):1986–92. doi: 10.3748/wjg.v20.i8.1986
40. Lengyel Z, Lovig C, Kommedal S, Keszthelyi R, Szekeres G, Battyáni Z, et al. Altered Expression Patterns of Clock Gene mRNAs and Clock Proteins in Human Skin Tumors. Tumour Biol J Int Soc Oncodevelopmental Biol Med (2013) 34(2):811–9. doi: 10.1007/s13277-012-0611-0
41. Kondratov RV, Antoch MP. The Clock Proteins, Aging, and Tumorigenesis. Cold Spring Harbor Symp quantitative Biol (2007) 72:477–82. doi: 10.1101/sqb.2007.72.050
42. Farhud D, Aryan Z. Circadian Rhythm, Lifestyle and Health: A Narrative Review. Iranian J Public Health (2018) 47(8):1068–76.
43. Stevens RG, Rea MS. Light in the Built Environment: Potential Role of Circadian Disruption in Endocrine Disruption and Breast Cancer. Cancer causes control CCC (2001) 12(3):279–87. doi: 10.1023/A:1011237000609
44. Lahti T, Merikanto I, Partonen T. Circadian Clock Disruptions and the Risk of Cancer. Ann Med (2012) 44(8):847–53. doi: 10.3109/07853890.2012.727018
45. Uchida Y, Hirayama J, Nishina H. A Common Origin: Signaling Similarities in the Regulation of the Circadian Clock and DNA Damage Responses. Biol Pharm Bull (2010) 33(4):535–44. doi: 10.1248/bpb.33.535
46. Rawla P. Epidemiology of Prostate Cancer. World J Oncol (2019) 10(2):63–89. doi: 10.14740/wjon1191
47. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654
48. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early Detection of Prostate Cancer: AUA Guideline. J Urol (2013) 190: (2):419–26. doi: 10.1016/j.juro.2013.04.119
49. Harris KS, Kerr BA. Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis. Stem Cells Int (2017) 2017:8629234. doi: 10.1155/2017/8629234
50. Polotti CF, Kim CJ, Chuchvara N, Polotti AB, Singer EA, Elsamra S. Androgen Deprivation Therapy for the Treatment of Prostate Cancer: A Focus on Pharmacokinetics. Expert Opin Drug Metab Toxicol (2017) 13(12):1265–73. doi: 10.1080/17425255.2017.1405934
51. Wade CA, Kyprianou N. Profiling Prostate Cancer Therapeutic Resistance. Int J Mol Sci (2018) 19(3):904. doi: 10.3390/ijms19030904
52. Martin SK, Pu H, Penticuff JC, Cao Z, Horbinski C, Kyprianou N. Multinucleation and Mesenchymal-To-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer. Cancer Res (2016) 76(4):912–26. doi: 10.1158/0008-5472.CAN-15-2078
53. Bumbaca B, Li W. Taxane Resistance in Castration-Resistant Prostate Cancer: Mechanisms and Therapeutic Strategies. Acta Pharm Sin B (2018) 8(4):518–29. doi: 10.1016/j.apsb.2018.04.007
54. Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E, et al. Circadian Disruption, Sleep Loss, and Prostate Cancer Risk: A Systematic Review of Epidemiologic Studies. Cancer epidemiology Biomarkers Prev Publ Am Assoc Cancer Research cosponsored by Am Soc Prev Oncol (2012) 21(7):1002–11. doi: 10.1158/1055-9965.EPI-12-0116
55. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Flüchter SH. Melatonin and 6-Sulfatoxymelatonin Circadian Rhythms in Serum and Urine of Primary Prostate Cancer Patients: Evidence for Reduced Pineal Activity and Relevance of Urinary Determinations. Clinica chimica acta; Int J Clin Chem (1992) 209(3):153–67. doi: 10.1016/0009-8981(92)90164-L
56. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, et al. Prospective Cohort Study of the Risk of Prostate Cancer Among Rotating-Shift Workers: Findings From the Japan Collaborative Cohort Study. Am J Epidemiol (2006) 164(6):549–55. doi: 10.1093/aje/kwj232
57. Stevens RG, Blask DE, Brainard GC, Hansen J, Lockley SW, Provencio I, et al. Meeting Report: The Role of Environmental Lighting and Circadian Disruption in Cancer and Other Diseases. Environ Health Perspect (2007) 115(9):1357–62. doi: 10.1289/ehp.10200
58. Fu L, Pelicano H, Liu J, Huang P, Lee C. The Circadian Gene Period2 Plays an Important Role in Tumor Suppression and DNA Damage Response In Vivo. Cell (2002) 111(1):41–50. doi: 10.1016/S0092-8674(02)00961-3
59. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, et al. Circadian Gene Mper2 Overexpression Induces Cancer Cell Apoptosis. Cancer Sci (2006) 97(7):589–96. doi: 10.1111/j.1349-7006.2006.00225.x
60. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin Resynchronizes Dysregulated Circadian Rhythm Circuitry in Human Prostate Cancer Cells. J pineal Res (2010) 49(1):60–8. doi: 10.1111/j.1600-079X.2010.00767.x
61. Li HX. The Role of Circadian Clock Genes in Tumors. OncoTargets Ther (2019) 12:3645–60. doi: 10.2147/OTT.S203144
62. Momma T, Okayama H, Saitou M, Sugeno H, Yoshimoto N, Takebayashi Y, et al. Expression of Circadian Clock Genes in Human Colorectal Adenoma and Carcinoma. Oncol Lett (2017) 14(5):5319–25. doi: 10.3892/ol.2017.6876
63. Benna C, Helfrich-Förster C, Rajendran S, Monticelli H, Pilati P, Nitti D, et al. Genetic Variation of Clock Genes and Cancer Risk: A Field Synopsis and Meta-Analysis. Oncotarget (2017) 8(14):23978–95. doi: 10.18632/oncotarget.15074
64. Harner-Foreman N, Vadakekolathu J, Laversin SA, Mathieu MG, Reeder S, Pockley AG, et al. A Novel Spontaneous Model of Epithelial-Mesenchymal Transition (EMT) Using a Primary Prostate Cancer Derived Cell Line Demonstrating Distinct Stem-Like Characteristics. Sci Rep (2017) 7:40633. doi: 10.1038/srep40633
65. Mao L, Dauchy RT, Blask DE, Slakey LM, Xiang S, Yuan L, et al. Circadian Gating of Epithelial-to-Mesenchymal Transition in Breast Cancer Cells via Melatonin-Regulation of GSK3β. Mol Endocrinol (Baltimore Md) (2012) 26(11):1808–20. doi: 10.1210/me.2012-1071
66. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, et al. Metastatic Progression of Prostate Cancer and E-Cadherin Regulation by Zeb1 and SRC Family Kinases. Am J Pathol (2011) 179(1):400–10. doi: 10.1016/j.ajpath.2011.03.028
67. Odero-Marah V, Hawsawi O, Henderson V, Sweeney J. Epithelial-Mesenchymal Transition (EMT) and Prostate Cancer. Adv Exp Med Biol (2018) 1095:101–10. doi: 10.1007/978-3-319-95693-0_6
68. Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, et al. Epithelial-Mesenchymal Transition in Prostate Cancer: An Overview. Oncotarget (2017) 8(21):35376–89. doi: 10.18632/oncotarget.15686
69. Hadadi E, Acloque H. Role of Circadian Rhythm Disorders on EMT and Tumour-Immune Interactions in Endocrine-Related Cancers. Endocrine-related Cancer (2021) 28(2):R67–r80. doi: 10.1530/ERC-20-0390
70. Xu W, Atkins MB, McDermott DF. Checkpoint Inhibitor Immunotherapy in Kidney Cancer. Nat Rev Urol (2020) 17(3):137–50. doi: 10.1038/s41585-020-0282-3
71. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer Statistics for the Year 2020: An Overview. Int J Cancer (2021) 149:778–89. doi: 10.1002/ijc.33588
72. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. J Natl Compr Cancer Network JNCCN (2009) 7(6):618–30. doi: 10.6004/jnccn.2009.0043
73. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal Cell Carcinoma. Nat Rev Dis Primers (2017) 3:17009. doi: 10.1038/nrdp.2017.9
74. Bhatt JR, Finelli A. Landmarks in the Diagnosis and Treatment of Renal Cell Carcinoma. Nat Rev Urol (2014) 11(9):517–25. doi: 10.1038/nrurol.2014.194
75. George CM, Stadler WM. The Role of Systemic Chemotherapy in the Treatment of Kidney Cancer. Cancer Treat Res (2003) 116:173–82. doi: 10.1007/978-1-4615-0451-1_10
76. Chappell JC, Payne LB, Rathmell WK. Hypoxia, Angiogenesis, and Metabolism in the Hereditary Kidney Cancers. J Clin Invest (2019) 129(2):442–51. doi: 10.1172/JCI120855
77. Solocinski K, Gumz ML. The Circadian Clock in the Regulation of Renal Rhythms. J Biol Rhythms (2015) 30(6):470–86. doi: 10.1177/0748730415610879
78. Zhang R, Lahens NF, Ballance HI, Hughes ME, Hogenesch JB. A Circadian Gene Expression Atlas in Mammals: Implications for Biology and Medicine. Proc Natl Acad Sci USA (2014) 111(45):16219–24. doi: 10.1073/pnas.1408886111
79. Mazzoccoli G, De Cata A, Piepoli A, Vinciguerra M. The Circadian Clock and the Hypoxic Response Pathway in Kidney Cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med (2014) 35(1):1–7. doi: 10.1007/s13277-013-1076-5
80. Zhou L, Luo Z, Li Z, Huang Q. Circadian Clock is Associated With Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma. Aging (2020) 12(14):14620–32. doi: 10.18632/aging.103509
81. Deng W, Zhu S, Zeng L, Liu J, Kang R, Yang M, et al. The Circadian Clock Controls Immune Checkpoint Pathway in Sepsis. Cell Rep (2018) 24(2):366–78. doi: 10.1016/j.celrep.2018.06.026
82. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol (2017) 71(1):96–108. doi: 10.1016/j.eururo.2016.06.010
83. Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary Tract Cancer Survival in Europe 1999-2007: Results of the Population-Based Study EUROCARE-5. Eur J Cancer (Oxford Engl 1990) (2015) 51(15):2217–30. doi: 10.1016/j.ejca.2015.07.028
84. Richters A, Aben KKH, Kiemeney L. The Global Burden of Urinary Bladder Cancer: An Update. World J Urol (2020) 38(8):1895–904. doi: 10.1007/s00345-019-02984-4
85. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder Cancer. Nat Rev Dis Primers (2017) 3:17022. doi: 10.1038/nrdp.2017.22
86. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, et al. Bladder Cancer. Lancet (London England) (2016) 388(10061):2796–810. doi: 10.1016/S0140-6736(16)30512-8
87. Massari F, Santoni M, Ciccarese C, Brunelli M, Conti A, Santini D, et al. Emerging Concepts on Drug Resistance in Bladder Cancer: Implications for Future Strategies. Crit Rev oncology/hematology (2015) 96(1):81–90. doi: 10.1016/j.critrevonc.2015.05.005
88. Sadiq Z, Varghese E, Büsselberg D. Cisplatin's Dual-Effect on the Circadian Clock Triggers Proliferation and Apoptosis. Neurobiol Sleep Circadian Rhythms (2020) 9:100054. doi: 10.1016/j.nbscr.2020.100054
89. Litlekalsoy J, Rostad K, Kalland KH, Hostmark JG, Laerum OD. Expression of Circadian Clock Genes and Proteins in Urothelial Cancer Is Related to Cancer-Associated Genes. BMC Cancer (2016) 16:549. doi: 10.1186/s12885-016-2580-y
90. Jia M, Su B, Mo L, Qiu W, Ying J, Lin P, et al. Circadian Clock Protein CRY1 Prevents Paclitaxel−Induced Senescence of Bladder Cancer Cells by Promoting P53 Degradation. Oncol Rep (2021) 45(3):1033–43. doi: 10.3892/or.2020.7914
91. Gordon RR, Nelson PS. Cellular Senescence and Cancer Chemotherapy Resistance. Drug resistance updates Rev commentaries antimicrobial Anticancer chemotherapy (2012) 15(1-2):123–31. doi: 10.1016/j.drup.2012.01.002
92. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of P53 Function and Stability by Phosphorylation. Mol Cell Biol (1999) 19(3):1751–8. doi: 10.1128/MCB.19.3.1751
93. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, et al. Molecular Dissection of Two Distinct Actions of Melatonin on the Suprachiasmatic Circadian Clock. Neuron (1997) 19(1):91–102. doi: 10.1016/S0896-6273(00)80350-5
94. Lissoni P, Viviani S, Bajetta E, Buzzoni R, Barreca A, Mauri R, et al. A Clinical Study of the Pineal Gland Activity in Oncologic Patients. Cancer (1986) 57(4):837–42. doi: 10.1002/1097-0142(19860215)57:4<837::AID-CNCR2820570425>3.0.CO;2-O
95. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Mao L, et al. Melatonin: An Inhibitor of Breast Cancer. Endocrine-Related Cancer (2015) 22(3):R183–204. doi: 10.1530/ERC-15-0030
96. Brzezinski A. Melatonin in Humans. New Engl J Med (1997) 336(3):186–95. doi: 10.1056/NEJM199701163360306
97. Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, et al. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. Int J Mol Sci (2017) 18(4):843. doi: 10.3390/ijms18040843
98. Dai M, Cui P, Yu M, Han J, Li H, Xiu R. Melatonin Modulates the Expression of VEGF and HIF-1 Alpha Induced by CoCl2 in Cultured Cancer Cells. J pineal Res (2008) 44(2):121–6. doi: 10.1111/j.1600-079X.2007.00498.x
99. Hardeland R. Melatonin in Aging and Disease -Multiple Consequences of Reduced Secretion, Options and Limits of Treatment. Aging Dis (2012) 3(2):194–225.
100. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: Reducing the Toxicity and Increasing the Efficacy of Drugs. J Pharm Pharmacol (2002) 54(10):1299–321. doi: 10.1211/002235702760345374
101. Korkmaz A, Reiter RJ. Epigenetic Regulation: A New Research Area for Melatonin? J pineal Res (2008) 44(1):41–4. doi: 10.1111/j.1600-079X.2007.00509.x
102. Bondy SC, Campbell A. Mechanisms Underlying Tumor Suppressive Properties of Melatonin. Int J Mol Sci (2018) 19(8):2205. doi: 10.3390/ijms19082205
103. Mills E, Wu P, Seely D, Guyatt G. Melatonin in the Treatment of Cancer: A Systematic Review of Randomized Controlled Trials and Meta-Analysis. J Pineal Res (2005) 39(4):360–6. doi: 10.1111/j.1600-079X.2005.00258.x
104. Lissoni P. Is There a Role for Melatonin in Supportive Care? Supportive Care Cancer Off J Multinational Assoc Supportive Care Cancer (2002) 10(2):110–6. doi: 10.1007/s005200100281
105. Tai S-Y, Huang S-P, Bao B-Y, Wu M-T. Urinary Melatonin-Sulfate/Cortisol Ratio and the Presence of Prostate Cancer: A Case-Control Study. Sci Rep (2016) 6(1):29606. doi: 10.1038/srep29606
106. Pienta KJ, Loberg R. The “Emigration, Migration, and Immigration” of Prostate Cancer. Clin Prostate Cancer (2005) 4(1):24–30. doi: 10.3816/CGC.2005.n.008
107. Chen PC, Tang CH, Lin LW, Tsai CH, Chu CY, Lin TH, et al. Thrombospondin-2 Promotes Prostate Cancer Bone Metastasis by the Up-Regulation of Matrix Metalloproteinase-2 Through Down-Regulating miR-376c Expression. J Hematol Oncol (2017) 10(1):33. doi: 10.1186/s13045-017-0390-6
108. Gong Y, Chippada-Venkata UD, Oh WK. Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression. Cancers (2014) 6(3):1298–327. doi: 10.3390/cancers6031298
109. Wang SW, Tai HC, Tang CH, Lin LW, Lin TH, Chang AC, et al. Melatonin Impedes Prostate Cancer Metastasis by Suppressing MMP-13 Expression. J Cell Physiol (2021) 236(5):3979–90. doi: 10.1002/jcp.30150
110. Pourhanifeh MH, Hosseinzadeh A, Juybari KB, Mehrzadi S. Melatonin and Urological Cancers: A New Therapeutic Approach. Cancer Cell Int (2020) 20(1):444. doi: 10.1186/s12935-020-01531-1
111. Li W, Wang Z, Chen Y, Wang K, Lu T, Ying F, et al. Melatonin Treatment Induces Apoptosis Through Regulating the Nuclear Factor-κb and Mitogen-Activated Protein Kinase Signaling Pathways in Human Gastric Cancer SGC7901 Cells. Oncol Lett (2017) 13(4):2737–44. doi: 10.3892/ol.2017.5785
112. Nopparat C, Chantadul V, Permpoonputtana K, Govitrapong P. The Anti-Inflammatory Effect of Melatonin in SH-SY5Y Neuroblastoma Cells Exposed to Sublethal Dose of Hydrogen Peroxide. Mech Ageing Dev (2017) 164:49–60. doi: 10.1016/j.mad.2017.04.001
113. Lin YW, Lee LM, Lee WJ, Chu CY, Tan P, Yang YC, et al. Melatonin Inhibits MMP-9 Transactivation and Renal Cell Carcinoma Metastasis by Suppressing Akt-MAPKs Pathway and NF-κb DNA-Binding Activity. J Pineal Res (2016) 60(3):277–90. doi: 10.1111/jpi.12308
114. Rudra DS, Pal U, Maiti NC, Reiter RJ, Swarnakar S. Melatonin Inhibits Matrix Metalloproteinase-9 Activity by Binding to its Active Site. J pineal Res (2013) 54(4):398–405. doi: 10.1111/jpi.12034
115. Mormont M-C, Levi F. Cancer Chronotherapy: Principles, Applications, and Perspectives. Cancer (2003) 97: (1):155–69. doi: 10.1002/cncr.11040
116. Lévi F, Okyar A. Circadian Clocks and Drug Delivery Systems: Impact and Opportunities in Chronotherapeutics. Expert Opin Drug Delivery (2011) 8(12):1535–41. doi: 10.1517/17425247.2011.618184
117. Payne JK. Altered Circadian Rhythms and Cancer-Related Fatigue Outcomes. Integr Cancer therapies (2011) 10(3):221–33. doi: 10.1177/1534735410392581
118. Fiorentino L, Ancoli-Israel S. Sleep Dysfunction in Patients With Cancer. Curr Treat Options Neurol (2007) 9(5):337–46. doi: 10.1007/s11940-007-0019-0
119. Hsu FM, Hou WH, Huang CY, Wang CC, Tsai CL, Tsai YC, et al. Differences in Toxicity and Outcome Associated With Circadian Variations Between Patients Undergoing Daytime and Evening Radiotherapy for Prostate Adenocarcinoma. Chronobiology Int (2016) 33(2):210–9. doi: 10.3109/07420528.2015.1130049
120. Hrushesky WJ, von Roemeling R, Lanning RM, Rabatin JT. Circadian-Shaped Infusions of Floxuridine for Progressive Metastatic Renal Cell Carcinoma. J Clin Oncol Off J Am Soc Clin Oncol (1990) 8(9):1504–13. doi: 10.1200/JCO.1990.8.9.1504
121. Lévi F. Circadian Chronotherapy for Human Cancers. Lancet Oncol (2001) 2(5):307–15. doi: 10.1016/S1470-2045(00)00326-0
122. Kobayashi M, Wood PA, Hrushesky WJ. Circadian Chemotherapy for Gynecological and Genitourinary Cancers. Chronobiology Int (2002) 19(1):237–51. doi: 10.1081/CBI-120002600
123. Negoro H, Iizumi T, Mori Y, Matsumoto Y, Chihara I, Hoshi A, et al. Chronoradiation Therapy for Prostate Cancer: Morning Proton Beam Therapy Ameliorates Worsening Lower Urinary Tract Symptoms. J Clin Med (2020) 9(7):2263. doi: 10.3390/jcm9072263
124. Forbes-Robertson S, Dudley E, Vadgama P, Cook C, Drawer S, Kilduff L. Circadian Disruption and Remedial Interventions: Effects and Interventions for Jet Lag for Athletic Peak Performance. Sports Med (Auckland NZ) (2012) 42(3):185–208. doi: 10.2165/11596850-000000000-00000
125. Mendt S, Gunga H-C, Felsenberg D, Belavy DL, Steinach M, Stahn AC. Regular Exercise Counteracts Circadian Shifts in Core Body Temperature During Long-Duration Bed Rest. NPJ Microgravity (2021) 7(1):1. doi: 10.1038/s41526-020-00129-1
126. Duffy JF, Czeisler CA. Effect of Light on Human Circadian Physiology. Sleep Med Clinics (2009) 4(2):165–77. doi: 10.1016/j.jsmc.2009.01.004
127. Jewett ME, Rimmer DW, Duffy JF, Klerman EB, Kronauer RE, Czeisler CA. Human Circadian Pacemaker is Sensitive to Light Throughout Subjective Day Without Evidence of Transients. Am J Physiol (1997) 273(5 Pt 2):R1800–9. doi: 10.1152/ajpregu.1997.273.5.R1800
128. Figueiro MG. Individually Tailored Light Intervention Through Closed Eyelids to Promote Circadian Alignment and Sleep Health. Sleep Health (2015) 1(1):75–82. doi: 10.1016/j.sleh.2014.12.009
129. Figueiro M, Saldo E, Rea M, Kubarek K, Cunningham J, Rea M. Developing Architectural Lighting Designs to Improve Sleep in Older Adults. Open Sleep J (2008) 1:40–51. doi: 10.2174/1874620900801010040
130. Figueiro MG, Bierman A, Plitnick B, Rea MS. Preliminary Evidence That Both Blue and Red Light can Induce Alertness at Night. BMC Neurosci (2009) 10(1):105. doi: 10.1186/1471-2202-10-105
131. Erren TC, Lewis P, Morfeld P. The Riddle of Shiftwork and Disturbed Chronobiology: A Case Study of Landmark Smoking Data Demonstrates Fallacies of Not Considering the Ubiquity of an Exposure. J Occup Med Toxicol (London England) (2020) 15:10. doi: 10.1186/s12995-020-00263-2
132. Atkinson G, Fullick S, Grindey C, Maclaren D. Exercise, Energy Balance and the Shift Worker. Sports Med (Auckland NZ) (2008) 38(8):671–85. doi: 10.2165/00007256-200838080-00005
133. Atkinson G, Edwards B, Reilly T, Waterhouse J. Exercise as a Synchroniser of Human Circadian Rhythms: An Update and Discussion of the Methodological Problems. Eur J Appl Physiol (2007) 99(4):331–41. doi: 10.1007/s00421-006-0361-z
134. Baehr EK, Eastman CI, Revelle W, Olson SH, Wolfe LF, Zee PC. Circadian Phase-Shifting Effects of Nocturnal Exercise in Older Compared With Young Adults. Am J Physiol Regulatory Integr Comp Physiol (2003) 284(6):R1542–50. doi: 10.1152/ajpregu.00761.2002
135. Youngstedt SD, Kripke DF, Elliott JA. Circadian Phase-Delaying Effects of Bright Light Alone and Combined With Exercise in Humans. Am J Physiol Regulatory Integr Comp Physiol (2002) 282(1):R259–66. doi: 10.1152/ajpregu.00473.2001
136. Weitzer J, Castaño-Vinyals G, Aragonés N, Gómez-Acebo I, Guevara M, Amiano P, et al. Effect of Time of Day of Recreational and Household Physical Activity on Prostate and Breast Cancer Risk (MCC-Spain Study). Int J Cancer (2021) 148(6):1360–71. doi: 10.1002/ijc.33310
137. Atkinson G, Drust B, Reilly T, Waterhouse J. The Relevance of Melatonin to Sports Medicine and Science. Sports Med (Auckland NZ) (2003) 33(11):809–31. doi: 10.2165/00007256-200333110-00003
138. Fuller PM, Lu J, Saper CB. Differential Rescue of Light- and Food-Entrainable Circadian Rhythms. Sci (New York NY) (2008) 320(5879):1074–7. doi: 10.1126/science.1153277
139. Saper CB, Fuller PM. Inducible Clocks: Living in an Unpredictable World. Cold Spring Harbor Symp quantitative Biol (2007) 72:543–50. doi: 10.1101/sqb.2007.72.008
140. Fu L, Kettner NM. The Circadian Clock in Cancer Development and Therapy. Prog Mol Biol Trans Sci (2013) 119:221–82. doi: 10.1016/B978-0-12-396971-2.00009-9
141. Battaglin F, Chan P, Pan Y, Soni S, Qu M, Spiller ER, et al. Clocking Cancer: The Circadian Clock as a Target in Cancer Therapy. Oncogene (2021) 40(18):3187–200. doi: 10.1038/s41388-021-01778-6
142. Penticuff JC, Woolbright BL, Sielecki TM, Weir SJ, Taylor JA 3rd. MIF Family Proteins in Genitourinary Cancer: Tumorigenic Roles and Therapeutic Potential. Nat Rev Urol (2019) 16(5):318–28. doi: 10.1038/s41585-019-0171-9
143. Zhu X, Suo Y, Fu Y, Zhang F, Ding N, Pang K, et al. In Vivo Flow Cytometry Reveals a Circadian Rhythm of Circulating Tumor Cells. Light: Sci Appl (2021) 10(1):110. doi: 10.1038/s41377-021-00542-5
Keywords: prostate cancer, kidney cancer, bladder cancer, genitourinary cancers, melatonin, chronotherapy, circadian rhythm, CLOCK proteins
Citation: Kaur P, Mohamed NE, Archer M, Figueiro MG and Kyprianou N (2022) Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers. Front. Oncol. 12:759153. doi: 10.3389/fonc.2022.759153
Received: 16 August 2021; Accepted: 24 January 2022;
Published: 09 March 2022.
Edited by:
Alexandre Zlotta, University of Toronto, CanadaReviewed by:
Jianbo Li, Case Western Reserve University, United StatesEdyta Reszka, Nofer Institute of Occupational Medicine, Poland
Armiya Sultan, Jamia Millia Islamia, India
Copyright © 2022 Kaur, Mohamed, Archer, Figueiro and Kyprianou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Natasha Kyprianou, Natasha.Kyprianou@mountsinai.org; Mariana G. Figueiro, Mariana.Figueiro@mountsinai.org